Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10296220 | 0.87 | MEN1 (0.44) | MEN1KMT2ARAB9ASMN1; SMN2POLB | |
| SCHEMBL7184636 | 0.77 | SMN1; SMN2 (0.45) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL31438780 | 0.70 | MEN1 (0.62) | MEN1KMT2A | |
| SCHEMBL1036238 | 0.70 | MEN1 (0.62) | MEN1KMT2A | |
| SCHEMBL7681591 | 0.68 | CXCR5 (0.48) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL2204112 | 0.67 | MEN1 (0.62) | MEN1KMT2AGRM5 | |
| SCHEMBL4273329 | 0.67 | HSD17B10 (0.33) | MEN1KMT2APOLBTDP1 | |
| SCHEMBL1006796 | 0.66 | LRRK2 (0.39) | GRM5ALDH1A1LMNA | |
| SCHEMBL31355236 | 0.65 | SMN1; SMN2 (0.52) | RAB9ASMN1; SMN2POLBALDH1A1CDC25B | |
| SCHEMBL15440287 | 0.65 | SMN1; SMN2 (0.52) | MEN1KMT2ARAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2283833-A2 | Amines and amides for the treatment of diseases | LA JOLLA PHARMACEUTICAL CO. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
| EP-1732531-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2006-02-02 | — | — | US | disclosed |
| WO-2005082343-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC1 | MEN1 4135/4885KMT2A 2165/4885RAB9A 3617/4885 |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | MEN1 4135/4885KMT2A 2165/4885RAB9A 3617/4885 |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC3, AOC2 | MEN1 3720/4885KMT2A 2663/4885RAB9A 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.